Cargando…

Engineered transcription-associated Cas9 targeting in eukaryotic cells

DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Gregory W., Kogenaru, Manjunatha, Keegan, Sarah, Haase, Max A. B., Kagermazova, Larisa, Arias, Mauricio A., Onyebeke, Kenenna, Adams, Samantha, Fenyö, David, Noyes, Marcus B., Boeke, Jef D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541143/
https://www.ncbi.nlm.nih.gov/pubmed/37781609
http://dx.doi.org/10.1101/2023.09.18.558319
_version_ 1785113851459534848
author Goldberg, Gregory W.
Kogenaru, Manjunatha
Keegan, Sarah
Haase, Max A. B.
Kagermazova, Larisa
Arias, Mauricio A.
Onyebeke, Kenenna
Adams, Samantha
Fenyö, David
Noyes, Marcus B.
Boeke, Jef D.
author_facet Goldberg, Gregory W.
Kogenaru, Manjunatha
Keegan, Sarah
Haase, Max A. B.
Kagermazova, Larisa
Arias, Mauricio A.
Onyebeke, Kenenna
Adams, Samantha
Fenyö, David
Noyes, Marcus B.
Boeke, Jef D.
author_sort Goldberg, Gregory W.
collection PubMed
description DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence specific but function constitutively; thus, they provide intrinsic spatial control over DNA targeting activities but naturally lack temporal control. Here we show that engineered Cas9 fusion proteins which bind to nascent RNAs near a protospacer can facilitate spatiotemporal coupling between transcription and DNA targeting at that protospacer: Transcription-associated Cas9 Targeting (TraCT). Engineered TraCT is enabled when suboptimal PAM interactions limit basal activity in vivo and when one or more nascent RNA substrates are still tethered to the actively transcribing target DNA in cis. We further show that this phenomenon can be exploited for selective editing at one of two identical targets in distinct gene loci, or, in diploid allelic loci that are differentially transcribed. Our work demonstrates that temporal control over Cas9’s targeting activity at specific DNA sites may be engineered without modifying Cas9’s core domains and guide RNA components or their expression levels. More broadly, it establishes RNA binding in cis as a mechanism that can conditionally stimulate CRISPR-Cas DNA targeting in eukaryotes.
format Online
Article
Text
id pubmed-10541143
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-105411432023-10-01 Engineered transcription-associated Cas9 targeting in eukaryotic cells Goldberg, Gregory W. Kogenaru, Manjunatha Keegan, Sarah Haase, Max A. B. Kagermazova, Larisa Arias, Mauricio A. Onyebeke, Kenenna Adams, Samantha Fenyö, David Noyes, Marcus B. Boeke, Jef D. bioRxiv Article DNA targeting Class 2 CRISPR-Cas effector nucleases, including the well-studied Cas9 proteins, evolved protospacer-adjacent motif (PAM) and guide RNA interactions that sequentially license their binding and cleavage activities at protospacer target sites. Both interactions are nucleic acid sequence specific but function constitutively; thus, they provide intrinsic spatial control over DNA targeting activities but naturally lack temporal control. Here we show that engineered Cas9 fusion proteins which bind to nascent RNAs near a protospacer can facilitate spatiotemporal coupling between transcription and DNA targeting at that protospacer: Transcription-associated Cas9 Targeting (TraCT). Engineered TraCT is enabled when suboptimal PAM interactions limit basal activity in vivo and when one or more nascent RNA substrates are still tethered to the actively transcribing target DNA in cis. We further show that this phenomenon can be exploited for selective editing at one of two identical targets in distinct gene loci, or, in diploid allelic loci that are differentially transcribed. Our work demonstrates that temporal control over Cas9’s targeting activity at specific DNA sites may be engineered without modifying Cas9’s core domains and guide RNA components or their expression levels. More broadly, it establishes RNA binding in cis as a mechanism that can conditionally stimulate CRISPR-Cas DNA targeting in eukaryotes. Cold Spring Harbor Laboratory 2023-09-18 /pmc/articles/PMC10541143/ /pubmed/37781609 http://dx.doi.org/10.1101/2023.09.18.558319 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Goldberg, Gregory W.
Kogenaru, Manjunatha
Keegan, Sarah
Haase, Max A. B.
Kagermazova, Larisa
Arias, Mauricio A.
Onyebeke, Kenenna
Adams, Samantha
Fenyö, David
Noyes, Marcus B.
Boeke, Jef D.
Engineered transcription-associated Cas9 targeting in eukaryotic cells
title Engineered transcription-associated Cas9 targeting in eukaryotic cells
title_full Engineered transcription-associated Cas9 targeting in eukaryotic cells
title_fullStr Engineered transcription-associated Cas9 targeting in eukaryotic cells
title_full_unstemmed Engineered transcription-associated Cas9 targeting in eukaryotic cells
title_short Engineered transcription-associated Cas9 targeting in eukaryotic cells
title_sort engineered transcription-associated cas9 targeting in eukaryotic cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541143/
https://www.ncbi.nlm.nih.gov/pubmed/37781609
http://dx.doi.org/10.1101/2023.09.18.558319
work_keys_str_mv AT goldberggregoryw engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT kogenarumanjunatha engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT keegansarah engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT haasemaxab engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT kagermazovalarisa engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT ariasmauricioa engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT onyebekekenenna engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT adamssamantha engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT fenyodavid engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT noyesmarcusb engineeredtranscriptionassociatedcas9targetingineukaryoticcells
AT boekejefd engineeredtranscriptionassociatedcas9targetingineukaryoticcells